Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA UCSF
Dates
study started
study ends around

Description

Summary

This prospective, observational, multicenter, patient registry will follow patients who are receiving treatment with Orenitram for the treatment of PAH for up to 78 weeks from Orenitram initiation

Keywords

Pulmonary Arterial Hypertension, PAH, Oral Treprostiinil, Orenitram, Treprostinil, Oral treprostinil

Eligibility

Locations

  • University of California - San Francisco
    Fresno California 94143 United States
  • Harbor UCLA Medical Center
    Torrance California 90502 United States
  • University of Southern California - Keck Medical Center
    Los Angeles California 90033 United States
  • Paloma Medical Group
    San Juan Capistrano California 92675 United States

Details

Status
in progress, not accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
United Therapeutics
ID
NCT03045029
Study Type
Observational [Patient Registry]
Participants
Expecting 300 study participants
Last Updated